Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) has shared an update.
Modalis Therapeutics reported no operating revenue for the quarter ended March 31, 2026, and narrowed its loss attributable to owners of the parent to ¥323 million from ¥652 million a year earlier. Basic loss per share improved to ¥3.64 as operating and ordinary losses roughly halved, indicating tighter cost controls despite the absence of sales.
The company’s financial position remained stable, with total assets at ¥2.94 billion and a high capital adequacy ratio of 93.8%, while net assets were largely unchanged. Modalis maintained its policy of not paying dividends and refrained from issuing a full-year earnings forecast, citing difficulty in making reliable estimates, underscoring ongoing uncertainty over the pace of monetizing its pipeline.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a Japan-based biotechnology company listed on the Tokyo Stock Exchange that develops genetic medicine technologies. The company focuses on research and development rather than commercialized products at this stage, and its financial profile reflects an early-stage biotech business heavily oriented toward R&D investment and capital preservation.
Average Trading Volume: 3,062,451
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.44B
For an in-depth examination of 4883 stock, go to TipRanks’ Overview page.